Guard Therapeutics International AB Share Price

Equities

GUARD

SE0021181559

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 17:00:00 17/07/2024 BST 5-day change 1st Jan Change
29.2 SEK -0.68% Intraday chart for Guard Therapeutics International AB -1.35% -18.44%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 339M 32.16M 2.47B
Net income 2024 * -99M -9.38M -722M Net income 2025 * -99M -9.38M -722M EV / Sales 2024 * -
Net cash position 2024 * 104M 9.86M 759M Net cash position 2025 * 5M 474K 36.47M EV / Sales 2025 * -
P/E ratio 2024 *
-4.33 x
P/E ratio 2025 *
-4.33 x
Employees 11
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.19%
More Fundamentals * Assessed data
Dynamic Chart
Guard Therapeutics Announces Scientific Journal American Journal of Physiology ? Renal Physiology Publishes Article Summarizing Important Preclinical Results of Its Clinical Drug Candidate RMC-035 CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update CI
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges MT
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035 CI
Guard Therapeutics International AB Appoints Nomination Committee for 2024 CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035 CI
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program CI
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA CI
Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation CI
More news
1 day-0.68%
1 week-1.35%
Current month-0.68%
1 month-12.57%
3 months+7.35%
6 months+16.80%
Current year-18.44%
More quotes
1 week
28.00
Extreme 28
30.00
1 month
27.80
Extreme 27.8
33.80
Current year
16.00
Extreme 16
41.00
1 year
6.28
Extreme 6.275
49.80
3 years
5.10
Extreme 5.1
112.50
5 years
5.10
Extreme 5.1
116.00
10 years
5.10
Extreme 5.1
13 700.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 30/11/18
Director of Finance/CFO 51 13/09/20
Chief Tech/Sci/R&D Officer 64 31/12/21
Members of the board TitleAgeSince
Chairman 68 30/04/21
Director/Board Member 61 28/05/19
Director/Board Member 48 30/11/22
More insiders
Date Price Change Volume
17/07/24 29.2 -0.68% 14,661
16/07/24 29.4 -0.68% 1,314
15/07/24 29.6 -0.67% 4,112
12/07/24 29.8 +0.68% 5,615
11/07/24 29.6 0.00% 2,900

Delayed Quote Nasdaq Stockholm, July 17, 2024 at 05:00 pm

More quotes
A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.
Calendar
More about the company